By Editor , 12 October 2026
Noah Medical Galaxy System Posts 92-96% Lung Biopsy Yield

San Carlos – October 12, 2026 -- Noah Medical's Galaxy System achieved a diagnostic yield of 92-96% in one hospital's early field experience and 96% in another's, according to whitepapers covering 165 patient procedures and 190 lesions. The data comes from D. Kyle Hogarth, MD, of the University of Chicago Medical Center, and Amit Mahajan, MD, of Inova Fairfax Hospital.

By Editor , 12 October 2026
Noah Medical's Galaxy System Hits 100% Tool-in-Lesion Accuracy in Trial

San Carlos – October 12, 2026 -- Noah Medical's Galaxy System robotic bronchoscopy platform achieved 100% tool-in-lesion accuracy and 100% successful navigation to small peripheral lesions in its first-in-human FRONTIER Study, according to final results published in the Official Journal of the Asian Pacific Society of Respirology.

By Editor , 12 October 2026
Noah Medical's Galaxy System Tops 5,000 U.S. Bronchoscopy Procedures

San Carlos, Calif. – October 12, 2026 -- Noah Medical has completed 5,000 procedures with its Galaxy System in the United States, roughly two years after the platform's first U.S. case in early 2023.

Dr. Abhinav Agrawal of Long Island Jewish Medical Center in New Hyde Park, NY, performed the milestone procedure. The company describes the Galaxy System as an image-integrated robotic-assisted bronchoscopy platform for early lung cancer detection.

By Editor , 12 October 2026
Noah Medical's Galaxy System Hits 96.7% Diagnostic Yield in CHEST Data

San Carlos, Calif. – October 12, 2026 -- Noah Medical's Galaxy robotic bronchoscopy platform delivered a 96.7% strict diagnostic yield in a 31-patient multi-center study, and an 89% yield with a cost-benefit ratio above 1 in a separate community hospital series, according to two data sets presented at the CHEST 2025 Annual Meeting in Chicago.

By Editor , 12 October 2026
Noah Medical Names Stanford's Krish Bhadra Chief Pulmonary Advisor

San Carlos, Calif. – October 12, 2026 -- Noah Medical has created a Chief Pulmonary Advisor role and filled it with Krish Bhadra, MD, an interventional pulmonologist at Stanford Medicine who has performed more than 2,300 robotic-assisted bronchoscopy procedures.

By Editor , 12 October 2026
Noah Medical Launches Galaxy II Bronchoscopy Software With Dual-Mode Imaging

San Jose – October 12, 2026 -- Noah Medical has commercially launched Galaxy II software for its robotic-assisted bronchoscopy (RAB) platform, adding Dual-Mode Imaging that lets physicians switch between High-Definition Digital Tomosynthesis (HD-DT) and Cone-Beam CT (CBCT) at any point in a procedure. The company says the update requires no added capital, complexity, or radiation.

By Editor , 12 October 2026
Noah Medical Completes First Commercial Galaxy Procedure in Asia

San Carlos – October 12, 2026 -- Noah Medical has completed its first commercial procedure in Asia with the Galaxy System at Prince of Wales Hospital in Hong Kong, moving the robotic bronchoscopy platform from clinical study to routine hospital use in the region.

Hong Kong hospital moves Galaxy from clinical study to commercial use

The hospital performed the first clinical use of the platform in Asia in December 2023. The new procedure marks the transition from clinical investigation to commercial integration, according to the company.

By Editor , 12 October 2026
Solventum Plans Separation of $1.4B Health Information Systems Unit

Eagan, Minn. – October 12, 2026 -- Solventum (NYSE: SOLV) said it intends to separate its Health Information Systems business, a healthcare software unit with $1.4 billion in annual sales, and is targeting completion within 12 to 18 months.

The move is the latest step in the company's three-phase transformation strategy. Solventum's Board of Directors and management expect the separation to leave a dedicated MedTech company focused on its MedSurg and Dental Solutions businesses.

By Editor , 12 October 2026
Profound's TULSA Beats Robotic RP on Penile Length in CAPTAIN Trial

Toronto – October 12, 2026 -- Men treated with whole-gland TULSA Procedure showed no median change in penile length at one month, compared with a median 0.65 cm reduction after robotic radical prostatectomy (RP), according to new data from the Level 1 CAPTAIN randomized controlled trial, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced.